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Abstract
Diverse physiological and therapeutic insults that increase the amount of unfolded or misfolded proteins in the
endoplasmic reticulum (ER) induce the unfolded protein response, an evolutionarily conserved protective mecha-
nism that manages ER stress. Glucose-regulated protein 78/immunoglobulin heavy-chain binding protein (GRP78/
BiP) is an ER-resident protein that plays a central role in the ER stress response and is the only known substrate of
the proteolytic A subunit (SubA) of a novel bacterial AB5 toxin. Here, we report that an engineered fusion protein,
epidermal growth factor (EGF)–SubA, combining EGF and SubA, is highly toxic to growing and confluent epidermal
growth factor receptor–expressing cancer cells, and its cytotoxicity is mediated by a remarkably rapid cleavage of
GRP78/BiP. Systemic delivery of EGF-SubA results in a significant inhibition of human breast and prostate tumor
xenografts in mouse models. Furthermore, EGF-SubA dramatically increases the sensitivity of cancer cells to the
ER stress–inducing drug thapsigargin, and vice versa, demonstrating the first example of mechanism-based syn-
ergism in the action of a cytotoxin and an ER-targeting drug.
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Introduction
Mammalian cells use evolutionarily conserved protective mechanisms
that attenuate stress induced by physiological and therapeutic insults.
Selective inhibition of such stress responses in cancer cells can pro-
vide a foundation for effective anticancer therapy. This might be par-
ticularly true for the unfolded protein response (UPR) that manages
endoplasmic reticulum (ER) stress induced by various drugs, oxygen
and glucose deprivation, alterations in Ca2+ fluxes, and by inhibition
of protein degradation. Initiation of the UPR is controlled by an ER
chaperone, glucose-regulated protein 78/immunoglobulin heavy-
chain binding protein (GRP78/BiP) [1,2]. Most GRP78/BiP resides
inside the ER lumen, although a certain fraction of the protein spans
the ER membrane, and in some cells, a fraction of the protein is in
the outer cell membrane [1,2]. Under normal conditions, GRP78/
BiP molecules are distributed between two main functions: 1) serv-
ing as chaperones for newly synthesized proteins that are folded in
the ER and 2) sequestering the ER luminal domains of the ER stress
transducers activating transcription factor 6, inositol-requiring
enzyme 1, and PKR-like ER kinase. Under ER stress conditions that
lead to enhanced production of misfolded/unfolded proteins, GRP78/
BiP distribution is shifted toward its chaperone functions. As a result,
released stress transducers initiate the UPR program, leading to activa-
tion of a complex interplay of survival and death signals, one of which
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leads to enhanced GRP78/BiP expression. If up-regulation of GRP78/
BiP is sufficient to handle both unfolded proteins and ER stress trans-
ducers, the cell survives. Alternatively, if ER stress persists, the cell dies.
Recently, it has been reported that GRP78/BiP is the only known
substrate of a novel bacterial AB5-type cytotoxin SubAB [3,4]. SubAB
comprises a single A subunit (SubA) with subtilisin-like proteolytic
activity and a pentamer of targeting B subunits. Surprisingly, al-
though partial inhibition of GRP78/BiP expression, through antisense
or RNA interference approaches, does not affect cell growth [5–7],
SubA-induced cleavage of GRP78/BiP leads to cell death [4]. We
reasoned that targeted delivery of SubA through receptor-mediated
endocytosis might be a suitable strategy for assaulting tumor cells,
which often overexpress GRP78/BiP [1]. It should be noted that
nearly all bacterial or plant toxins explored for cancer therapy so far,
such as truncated diphtheria toxin (DT) or Shiga-like toxin (StxA),
worked through the inhibition of protein synthesis [8]. We hypoth-
esized that because of its unique mechanism of action, SubA might
synergize with ER stress–inducing drugs, resulting in a more severe in-
sult to cancer cells.
To test this hypothesis, we fused SubA to epidermal growth factor
(EGF), whose receptor (EGFR) is frequently overexpressed in tumor
cells, and evaluated the resulting EGF-SubA fusion protein in vitro
and in vivo. We report here that EGF-SubA acts synergistically with
drugs that significantly upregulate BiP expression, providing a possi-
bility of the development of combination regimens for effective anti-
cancer therapy.
Materials and Methods
Construction of EGF-SubA Fusion Protein
DNA encoding the enzymatic subunit of SubAB (SubA) without a
leader sequence (a M1-A21 N-terminal fragment) was amplified by
polymerase chain reaction (PCR) from the pK184/SubA plasmid en-
coding the full-length subunit A [4] and cloned in-frame with a codon-
optimized human EGF cDNA (kindly provided by Dr. P. T. Pienkos,
Molecular Logix, Woodlands, TX) into the pET/Hu-R4C(G4S)3 vec-
tor for bacterial expression of proteins with Cys-tag [9,10]. EGF-SubA
and three control proteins (SubA, EGF-ciSubA, and EGF-StxA de-
scribed in Figure W1) were expressed in Escherichia coli strain BL21
(DE3), recovered from inclusion bodies and refolded through dialysis
under RedOx conditions as described for Cys-tagged proteins [9]. All
proteins were purified through ion exchange chromatography (1-ml
prepacked Sepharose FF columns; GE Healthcare, Waukesha, WI).
Fluorescent Tracers
SH-directed modification of Cys-tagged proteins was done accord-
ing to the standard protocol [9]. Briefly, the reactive SH group of C4
in Cys-tag was activated by a 20-minute treatment with equimolar
DTT in 0.1 M Tris-HCl pH 8.0 at 25°C and then reacted for 1 hour
at 25°C with a maleimide derivative of a fluorescent dye as follows.
To develop fluorescent EGF-SubA*, EGF-SubA was reacted with a
one molar equivalent of Alexa Fluor 594 maleimide (Invitrogen,
San Diego, CA) and purified by gel filtration on Ultrogel AcA 202
(Pall BioSepra, France). To synthesize f luorescent scVEGF*, single-
chain vascular endothelial growth factor (scVEGF) [9,10] was re-
acted with a 1.5-fold molar excess of Alexa Fluor 594 maleimide
and purified by reverse-phase high-pressure liquid chromatography on
a protein C-4 column (Vydac, Hesperia, CA). Cys-tagged EGF [10] was
modified with a twofold molar excess of Oregon Green 488 maleimide
(OrG; Invitrogen) andwas purified on PD-10 column (GEHealthcare),
resulting in a fluorescent EGF-OrG tracer. The protein concentra-
tions of the fluorescent tracers were determined from integral intensity
peaks on reverse-phase high-pressure liquid chromatography profiles
at 214 nm. The concentrations of Alexa Fluor 594 and Oregon Green
488 were determined spectrophotometrically. The functional activ-
ity of all fluorescent tracers was tested in tissue culture as described
[10,11] and was found to be no less than 80% of the corresponding
unmodified protein.
Tissue Culture
MDA231luc cells were developed and cultured as described [10].
F98-EGFR, F98-EGFR(F), and F98 rat glioma cells (kindly provided
by Dr. R. Barth, the Ohio State University) were maintained in 50:50
(vol%)Dulbecco’s modified Eagle medium/F-12 (Gibco, Billings, MT)
supplemented with 5% FBS (HyClone, Logan, UT) and 2 mM
L-glutamine (Gibco). PC3 and MCF-7 cells (obtained from ATCC,
Manassas, VA) were maintained in F-12 (Sigma, St. Louis, MO) or
minimum essential medium (Gibco), respectively, with 10% FBS
and 2 mM L-glutamine. U266-B1 cells (obtained from ATCC) were
grown in RPMI (Sigma), 20% FBS, and 2 mM L-glutamine. All cells
were maintained at 5% CO2 at 37°C.
Cell Growth Inhibition
Cells were plated in 96-well plates at a density of 2000 to 5000 cells
per well in 50 μl per well of the corresponding media. Various concen-
trations of proteins, drugs, or mixtures thereof were added to cells in
triplicate wells 20 hours later to make a total volume of 0.1 ml per well,
and cells were incubated under standard culture conditions for 72 to
96 hours. Viable F98, F98-EGFR, and F98-EGFR(F) cells and conflu-
ent MDA231luc cells were determined using a 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolinium bromide assay (Sigma) according to
the manufacturer’s instructions. Viable PC3, MCF-7, U266-B1, and
subconfluentMDA231luc cells were detected byCellTiter 96 AQueous
One Solution Cell Proliferation assay (Promega, Madison, WI). The
half-maximal inhibitory concentration (IC50) values were determined
by plotting the viable cell numbers (as percent of control) versus the
concentration of a cytotoxic compound.
Fluorescent Microscopy
F98 and F98-EGFR(F) cells were plated on glass slides in complete
culture medium 20 hours before the experiment. Fluorescent EGF-
SubA* and control tracers EGF-OrG and scVEGF* were added to cells
in complete culture medium to f inal concentrations of 2 nM and in-
cubated at 37°C for 10 minutes. Cells were washed with PBS, fixed in
fresh 4% formaldehyde (Polysciences, Warrington, PA) for 10 minutes
at room temperature, and mounted in mounting medium for f luores-
cence supplemented with 4′,6-diamidino-2-phenylindole (DAPI) for
nuclear counterstaining (Vector Laboratories, Burlingame, CA). Slides
were observed with a 43× oil objective on a Zeiss Axiovert microscope
(Zeiss, Oberkochen, Germany).
Western Blot Analysis
Total protein in clarified cell lysates was determined by a micro-
BCA assay (Pierce, Rockford, IL). Equal amounts of total protein
(25-40 μg per lane, depending on the antibody) were separated by
SDS-PAGE and transferred to nitrocellulose. GRP78/BiP antibody
H-129 (sc-13968; Santa Cruz Biotechnology, Santa Cruz, CA) that
reacts with the intact BiP and its 28-kDa fragment was used at the
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beginning of this work. In the course of the study, the H-129 antibody
lost reactivity. After having tested several lots of H-129 from Santa Cruz
Biotechnology, none of which showed satisfactory reactivity and spec-
ificity, we switched to a different supplier. The rest of the study was
done with GRP78/BiP antibody from R&D Systems (Minneapolis,
MN; clone 474421, no. MAB4846) that recognizes the intact BiP
and its 44-kDa fragment. N-terminal β-actin and phosphotyrosine pY
(clone PT-66) antibodies were from Sigma. Ms-Spectrin (nonerythroid,
α-fodrin) antibody was from Chemicon (Millipore, Billerica, MA).
Cleaved caspase-7 (Asp 198) antibody was from Cell Signaling (Beverly,
MA). Active caspase-3 antibody was from AbCam (Cambridge, MA).
Secondary HRP-conjugated antibodies and the ECL Plus detection kit
were from GE Healthcare. Blot images were captured by a gel docu-
mentation system (Streamcare, Rochester, NY) and analyzed by Kodak
1D Image Analysis Software (Kodak, Rochester, NY). Intact BiP signal
intensities were normalized to the corresponding β-actin signals.
In-cell Western
Cells were plated onto 96-well Optilux Black/clear bottom tissue
culture–treated plates (BD Falcon, Franklin Lakes, NJ) at a density of
20,000 cells per well. EGF-SubA was serially diluted in complete cul-
ture medium and added to cells in triplicate wells 20 hours later.
Cells were incubated at 37°C for 24 hours then washed once with
PBS, fixed in fresh 4% formaldehyde (Polysciences) for 10 minutes
at room temperature, permeabilized in PBS/0.1% Triton X-100, and
blocked in Odyssey Blocking Buffer (Li-COR, Lincoln, NE) for
2 hours. Active caspase-3 antibody (AbCam) diluted 1:500 was added
to cells for 2 hours at room temperature, followed by secondary goat
anti–rabbit IRDye-800CWantibody (Li-COR) diluted 1:500 and sup-
plemented with Sapphire700 and DraQ5 (both from Li-COR) for
nonspecific cell staining. After 1 hour of incubation, cells were exten-
sively washed with PBS–0.1% Tween-20, air-dried, and scanned simul-
taneously at 700 and 800 nm using a Starion FLA-9000 imager
(FujiFilm Medical Systems, New York, NY). The fluorescent signal
of active caspase-3 from each well was quantified and normalized by
the total protein content per well.
Fluorescent Apoptosis Assays
Fluorescent apoptosis assays were done as described [12].
Induction of EGFR Tyrosine Phosphorylation
Induction of EGFR tyrosine phosphorylation was done as de-
scribed [11]. Briefly, F98-EGFR(F) cells were grown in 24-well plates
to approximately 80% confluence. After overnight serum starvation,
cells were incubated with indicated amounts of EGF (Sigma) or
EGF-SubA for 10 minutes, lysed, and analyzed by Western blot anal-
ysis with phosphotyrosine-specific antibody (clone PT-66; Sigma).
Mice
Five- to six-week-old severe combined immunodeficient (SCID)/
Ncr (BALB/c background) mice were from Charles River Laborato-
ries (Wilmington, MA). Orthotopic breast tumors were established
by inoculation of 5 × 106 MDA231luc cells in the region of mouse
fat pad. PC3 cells were injected subcutaneously in left f lanks at 3 ×
106 cells per mouse. Tumors were measured with calipers, and the
tumor volume was calculated as V = 0.52 × L ×W × H . The protocol
for the animal studies was reviewed and approved by the Institutional
Animal Care and Use Committee at the University of Connecticut
Health Center.
Immunohistochemistry
Immunohistochemistry was done as described [10].
Results
EGF-SubA Fusion Protein Cleaves Intracellular GRP78/BiP
EGF-SubA was expressed in E. coli as an insoluble protein, re-
folded, and purified through ion exchange chromatography to more
than 95% purity (Figure W2A). Rat glioma F98 cells engineered to
express 1.4 × 106 human EGFR per cell (F98-EGFR(F) cells; Table 1)
were used to test its functional activity. EGF-SubA induced EGFR
tyrosine autophosphorylation in F98-EGFR(F) cells, although less
efficiently, but still in the same concentration range as recombinant
EGF (Figure 1A), attesting to the functional activity of the EGF
moiety. EGF-SubA retained the proteolytic activity and specificity
of the parental bacterial toxin SubAB5, as judged by its ability to
cleave recombinant 78-kDa GRP78/BiP between L416 and L417,
yielding a 44- and a 28-kDa fragments (Figure 1B).
To evaluate EGFR-mediated internalization of EGF-SubA in F98-
EGFR(F) cells by f luorescent microscopy, we made a f luorescent
tracer EGF-SubA*. EGF-SubA, as well as all control proteins de-
veloped for this study (Figure W1), was expressed with a cysteine-
containing Cys-tag designed for site-specific conjugation of various
payloads [9]. As we previously reported, SH-directed modification
of recombinant Cys-tagged growth factors carried out under defined
conditions preserves the functional activity of the modified proteins,
including their ability to bind to cognate receptors [9–12]. Indeed,
we found that site-specifically modified and unmodified EGF-SubA
displayed a very similar activity in a standard cytotoxicity assay
(Figure W2B).
EGF-SubA* accumulated in F98-EGFR(F) cells at low nanomolar
concentrations as efficiently as f luorescent EGF (Figure 1C ). To
prove that the observed uptake was EGFR-mediated, and not a result
of enhanced endocytic activity of the transfected glioma cells, we used
an unrelated growth factor scVEGF* [10] site-specifically labeled with
Alexa Fluor 594. scVEGF* administered at the same concentration
failed to accumulate in F98-EGFR(F) cells (Figure 1C ). Another spec-
ificity control, F98 cells lacking EGFR expression, did not show any
detectable amount of EGF-SubA* even after 1 hour of incubation with
as high as 125 nM tracer (Figure 1C). These data indicate that bacte-
rially expressed EGF-SubA is capable of rapid and selective accumula-
tion in EGFR-positive cells.
To test EGFR-mediated proteolytic activity of EGF-SubA, we se-
lected human prostate cancer (PC3) and human breast cancer
(MDA231luc) cells, both expressing moderate levels of EGFR (ap-
proximately 2 × 105 EGFR per cell; Table 1) and similar levels of
BiP (Figure W3). EGF-SubA induced rapid cleavage of BiP in these
Table 1. EGF-SubA Toxicity for Cancer Cell Lines with Varying EGFR Expression.
Cell Line EGF-SubA
Toxicity (IC50)
EGFR/Cell Reference
F98 rat glioma 6 nM None [36]
F98-EGFR rat glioma 20 pM 105 [36]
F98-EGFR(F) rat glioma 20 pM 1.4 × 106 [11]
MCF-7 human breast cancer 5 nM 1.5 × 104 [37]
MDA231luc human breast cancer 30 pM 2 × 105 Figure W2
[38], for MDA-MB-231
PC3 human prostate 1 pM ∼2 × 105 Figure W2
U266-B1 human myeloma >6 nM None Figure W2
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cells (Figure 2, A and B). However, the time course of EGF-SubA–
induced alterations in BiP levels revealed a cell-specific pattern of
destruction and de novo synthesis of BiP. In PC3 cells, the cleavage
was remarkably fast, with a substantial decrease of intact BiP after as
short as 5 minutes of the treatment. Band intensity analysis revealed
that the amount of intact BiP dropped 14-fold during the first 3 hours
of exposure. Notably, the level of intact BiP was not restored in PC3
cells during the 24-hour course of treatment (Figure 2A). In contrast,
we did not observe any substantial BiP cleavage in MDA231luc until
1.5 hours of exposure (Figure 2B). The maximal cleavage in both cell
types was reached at the same time (by 3 hours); however, MDA231luc
cells, unlike PC3, responded to continuous BiP cleavage by a significant
up-regulation of BiP expression. The level of intact BiP in MDA231luc
was restored by 9 hours, and by 24 hours of treatment, it was increased
approximately twofold over the level of control untreated cells. The in-
ability of an equivalent amount of untargeted SubA to induce BiP
cleavage in MDA231luc until 24 hours of treatment (Figure W4A)
confirmed that EGFR-mediated endocytosis was critical for efficient
delivery of EGF-SubA into the cell.
The different susceptibilities of MDA231luc and PC3 cells to
EGF-SubA were confirmed by dose-finding experiments, when cells
were exposed to varying amounts of EGF-SubA for 72 hours. We
found that BiP cleavage and the appearance of a 44-kDa BiP frag-
ment in PC3 cells was detectable at 0.1 pM EGF-SubA, whereas
at least a fourfold higher concentration was required for MDA231luc
cells (Figure W4B).
EGF-SubA Is a Powerful Cytotoxin
The cytotoxicity of SubAB holotoxin was attributed to its ability
to selectively cleave BiP [3,4]. In agreement with these data, PC3
cells that displayed the fastest EGF-SubA–induced BiP cleavage
seemed to be the most sensitive to EGF-SubA toxicity among all
tested cell lines, with an IC50 value of 1 pM (Table 1). As expected
from Western blot analysis, MDA231luc cells were less sensitive
(IC50 = 30 pM). To confirm a causative role of BiP cleavage in these
effects, we constructed a control fusion protein, EGF-ciSubA, con-
taining a catalytically inactive (ci) mutant of SubA, which failed to
inhibit the growth of PC3 cells (Figure W4C ).
The high cytotoxicity of EGF-SubA for tumor cells was EGFR-
dependent because EGFR-negative F98 or U266-B1 cells were 200-
to 6000-fold less sensitive to EGF-SubA than MDA231luc or PC3
cells, respectively (Table 1). An EGFR-mediated mechanism of the
effects of EGF-SubA on MDA231luc cells was further confirmed by
the absence of toxicity of untargeted SubA (Figure 2C ). These data
are in an agreement with a previously published observation that SubA
subunit alone, without the targeting B subunit, was not toxic to suscep-
tible Vero cells [4]. Finally, a competition assay, in which EGF rescued
cells from EGF-SubA–induced toxicity in a dose-dependent manner
(Figure 2D), confirmed an EGFR-mediated mechanism of EGF-
SubA–induced toxicity.
Although EGFR is necessary to mediate the toxicity of EGF-SubA,
the relationship between the levels of EGFR expression and EGF-SubA–
induced toxicity is apparently more complex than a simple direct corre-
lation. We found that two EGFR-expressing F98 cell lines, F98-EGF
and F98-EGFR(F), displayed the same susceptibility to EGF-SubA,
with IC50 values of 20 pM each, despite one order of magnitude dif-
ference in the EGFR expression levels. Additional evidence was ob-
tained by analyzing two human breast carcinoma cell lines, namely,
MDA231luc and MCF-7, with moderate (∼2 × 105 EGFR per cell) and
low (∼104 EGFR per cell) EGFR expressions, respectively. The suscep-
tibility of these cells to EGF-SubA differed more than 150-fold, despite
only an approximately 20-fold difference in EGFR expression levels.
Interestingly, at low EGF-SubA concentrations, two sequential
half doses of cytotoxin given 24 hours apart were more effective
Figure 1. EGF-SubA is functionally active. (A) Induction of EGFR tyrosine phosphorylation in F98-EGFR(F) cells. (B) Cleavage of recom-
binant BiP followed by reducing SDS-PAGE was done as described [3]. Proteins from the gel were transferred onto polyvinylidene fluo-
ride membrane; the 28-kDa fragments were excised, washed, and subjected to N-terminal sequencing using Edman chemistry on an
Applied Biosystems Procise automated sequencer (Foster City, CA). In both cases, the sequence was L-D-V-C-P, which is consistent
with cleavage of BiP between L416 and L417. (C) Each fluorescent tracer was added to F98-EGFR(F) cells to a final concentration of 2 nM
for 10 minutes. EGF-SubA* was added to control F98 cells at a concentration of 125 nM for 1 hour. Red indicates EGF-SubA*; green,
EGF-OrG; red, scVEGF*; blue, nuclei (DAPI). Scale bar, 20 μm.
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against MDA231luc cells than an equivalent amount given as a single
dose (Figure W5). It is possible that the second half dose of EGF-
SubA given in 24 hours was more effective than the full dose in
blunting a protective cellular response owing to the kinetics of BiP
up-regulation in these cells by 24 hours after the first exposure
(Figure 2B).
Importantly, a 96-hour exposure of 100% confluent MDA231luc
cells to EGF-SubA resulted in a dose-dependent decrease in the
numbers of viable cells, as judged both by a 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolinium bromide dye assay and by directly
counting the cells (Figure 2E ), indicating that cell growth is not re-
quired for EGF-SubA action. In contrast, the activity of other cyto-
toxins is reported to be dependent on cell growth [13,14]. Indeed, a
control fusion of EGF with the A subunit of Shiga toxin (EGF-StxA;
Figure W1) was not effective against conf luent cells (Figure 2E ). The
EGF and StxA domain activity, as well as the cytotoxicity of EGF-
StxA fusion protein for growing MDA231luc cells, was confirmed in
separate experiments (Figure W6).
EGF-SubA induced massive apoptosis in PC3 cells, as detected by
in-cell Western analysis of active caspase-3 (Figure 2F ). Similarly, the
SubAB holotoxin was reported to induce apoptosis in Vero cells [15].
EGF-SubA Inhibits Tumor Growth
To evaluate the activity of EGF-SubA in vivo, we used PC3 and
MDA231luc tumors grown in SCID mice. EGF-SubA is a large pro-
tein of 45 kDa; therefore, first, we established if it was capable of
Figure 2. EGF-SubA–induced cytotoxicity is EGFR-dependent. Selective cleavage of BiP in PC3 cells (A) and MDA231luc cells (B). Cells
were plated in six-well plates, 0.5 million/well, exposed to 1 nM EGF-SubA 20 hours later. Equal amounts of clarified cytosols (40 μg of
total protein) were analyzed by Western blot analysis using antibody specific for BiP from R&D Systems (A) or Santa Cruz Biotechnology
(B). (C) MDA231luc cells were plated in triplicate wells of 96-well plates, 2000 cells per well, and exposed to EGF-SubA, or untargeted
SubA, 20 hours later. Cell viability was determined after 72 hours. (D) MDA231luc cells were plated as described in panel C. Varying
amounts of competitor EGF were mixed with EGF-SubA and added to cells to a final concentration of 50 pM EGF-SubA. Cell viability was
determined after 72 hours. (E) Ninety-six hours after plating, after reaching 100% confluence, MDA231luc cells were exposed to EGF-
SubA or EGF-StxA. Cell viability was determined after 5 days of treatment. At the highest concentration of EGF-SubA, cells were directly
counted in Coulter Counter, and a 66% decrease in the number of treated versus control cells (66,800 vs 198,000 cells per well) corre-
sponded to the results of the viability assay. (F) In-cell Western analysis of caspase-3 activation in PC3 cells after a 24-hour exposure to
varying amounts of EGF-SubA.
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extravasating it from tumor blood vessels and penetrating the tumor
tissue. MDA231luc tumor–bearing mice were injected with fluores-
cent EGF-SubA* (125μg/kg, intravenously) 1 hour before termination.
Fluorescent immunohistochemical analysis of tumor cryosections re-
vealed that most Alexa Fluor 594 fluorescence was associated with
EGFR-positive cells within the tumor (EGFR staining; Figure 3A), with
a small amount associated with endothelial cells in tumor blood vessels
(VEGFR-2 and CD31 staining; Figure 3A).
To establish if therapeutically relevant amounts of EGF-SubA could
be accumulated in tumor tissue, we selected a regimen of several con-
secutive intraperitoneal (IP) injections, at a dose of 125 μg/kg per in-
jection. After 10 to 12 days of tumor cell implantation, when tumors
became palpable, mice (n = 5) received four IP injections of EGF-SubA.
The first three injections were done every other day, with the last injec-
tion done 1 week after the third injection. Control mice (n = 5) were
injected IP with saline. The treatment was well tolerated, with no clini-
cal signs of toxicity observed in any treated groups.
A significant inhibition of tumor growth in both tumor models
was detected after the first three injections; however, it did not result
in complete tumor regression. Consistent with the results obtained in
tissue culture experiments, PC3 tumors seemed to be more respon-
sive to EGF-SubA treatment than MDA231luc tumors (Figure 3B).
The accumulated experience with EGF-targeted toxins suggests that
an increased EGF-SubA dosage could lead to tumor regression but
would also result in unacceptable nonspecific organ toxicity. Current
approaches to achieving higher cytotoxin efficiency are local delivery
and/or PEGylation of the cytotoxin [16]. Another possibility would
be combining a cytotoxin with a synergistic drug. We hypothesized
Figure 3. EGF-SubA inhibits tumor growth. (A) MDA231luc tumor-bearing mouse injected intravenously with fluorescent EGF-SubA*
(125 μg/kg), 1 hour before termination. To identify cells with red fluorescence, tumor cryosections were stained for EGFR, VEGFR-2,
or CD31. Staining was developed with Alexa Fluor 488 by the TSA amplification technique (Molecular Probes, Invitrogen, Carlsbad, CA).
Red indicates EGF-SubA*; blue, nuclei (DAPI). (B) Growth of PC3 (left panel) and MDA231luc (right panel) tumors in SCID (Balb/c back-
ground) mice. Arrows indicate days of injections with EGF-SubA.
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that, owing to its unique mechanism of action, EGF-SubA could syn-
ergize with ER stress–inducing drugs.
EGF-SubA Synergizes with a Strong ER Stress Inducer
In searching for a potential synergistic drug, we tested thapsigargin,
a known cytotoxic inducer of ER stress [17]. Thapsigargin inhibits
ER Ca2+-dependent ATPase, leading to a depletion of ER Ca2+ stor-
age, which, in turn, decreases the activity of Ca-dependent chaperones
leading to an increase in unfolded proteins and the corresponding
induction of UPR signaling. As expected, treatment of MDA231luc
with thapsigargin resulted in a time-dependent increase of BiP
(Figure 4A). However, in cells exposed to a combination of EGF-
SubA and thapsigargin, cleavage of BiP led to accumulation of the
BiP fragment but not to net up-regulation of the intact protein, as
was observed for either thapsigargin (Figure 4A) or EGF-SubA alone
(Figure 2B). Thus, the combination of EGF-SubA and thapsigargin
effectively sabotaged the UPR defense mechanism.
To evaluate the relationship between the effects of thapsigargin and
EGF-SubA, we used an approach, pioneered by Berenbaum [18], to
analyze interactions between the drugs as either additive, synergistic,
or antagonistic. In this approach, a mixture of two drugs is prepared
at a ratio based on their corresponding IC50 values, and then the
IC50 value for each drug is determined from a dose-dependent experi-
ment with this mixture. If the drugs are additive, it will lead to an
approximately twofold decrease in the IC50 value for each drug in
combination relative to the drugs alone. The sum (S ) of fractional
IC50 (a ratio of IC50 for a drug in a combination to IC50 for drug alone)
serves as a quantitative criterion, indicating synergism when S < 1, ad-
ditivity when S ∼ 1, and antagonismwhen S > 1.To apply this approach,
thapsigargin alone or in combination with EGF-SubA at a molar ratio
of 1000:1 was serially diluted in complete culture medium and added
to MDA231luc cells. We found that the combination of these two
compounds was dramatically more effective than either drug alone
(S = 0.15), with fractional IC50 values of 0.056 for thapsigargin and
0.094 for EGF-SubA, respectively. Synergism between EGF-SubA
and thapsigargin was particularly striking because of the essentially non-
toxic concentrations of each compound alone, whereas their combina-
tion at the same concentrations was extremely cytotoxic (Figure 4B).
An analysis of overall caspase activity, as well as the combined activity
of executioner caspases-3 and -7, supports a synergistic enhancement of
apoptosis by the combination of thapsigargin and EGF-SubA (Fig-
ure 4C ). Further analysis revealed that the EGF-SubA/thapsigargin
combination led to an increased cleavage of α-fodrin, a known substrate
of caspase-3 [19] but not to a notable increase of the cleaved, activated
form of caspase-7 (Figure 4D), indicating that the synergistic effect
might be preferentially mediated by caspase-3. Interestingly, a 24-hour
treatment with EGF-SubA alone did not result in any significant cleav-
age of α-fodrin or procaspase-7.
Figure 4. EGF-SubAenhancescytotoxic effects of theERstress inducer thapsigargin. (A)MDA231luccells plated in six-well plates, 0.5million/
well, and, 20 hours later, were exposed to 1 nM EGF-SubA, 2.5 μM thapsigargin, or their combination for 18 to 20 hours. Clarified cytosol
fractions were analyzed for BiP cleavage as described in the legend to Figure 1 (BiP antibody was from Santa Cruz Biotechnology).
(B) MDA231luc cells were plated in 96-well plates at 2000 cells per well. Twenty hours later, cells in triplicate wells were exposed to
varying amounts of thapsigargin alone (Thaps) or in combination with EGF-SubA at a molar ratio of 1000:1. Viability was determined
72 hours later. (C and D) MDA231luc cells were plated and treated as in panel A. Clarified cytosols were analyzed for caspase activity
using fluorescent pan-caspase AC-2 and specific caspase 3/7 substrates (C) and cleavage of α-fodrin (25 μg total protein per lane) and
caspase-7 (40 μg total protein per lane) (D).
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To further elucidate the role of BiP up-regulation in response to a
EGF-SubA/drug combination, we tested two known chemotherapeu-
tics, doxorubicin and bortezomib. Doxorubicin is not known to induce
ER stress, whereas bortezomib inhibits protein degradation by pro-
teosomes and induces ER stress and the UPR in some experimental sys-
tems [20]. When tested on MDA231luc cells, neither doxorubicin nor
bortezomib was very effective in the induction of BiP up-regulation
(Figure W7A), particularly when compared with thapsigargin (Fig-
ure 4A). Using the same approach as described above for the EGF-
SubA/thapsigargin combination, we observed marginally synergistic
interactions between EGF-SubA and either bortezomib or doxorubicin
(Figure W7, B and C ), with the corresponding sums of fractional
IC50 values S = 0.7 and 0.8. Thus, it seems that a significant up-
regulation of BiP is a specific requirement for synergism in EGF-
SubA/drug combinations.
Discussion
We report here that EGF-SubA is cytotoxic to both growing and
confluent EGFR-expressing cells in the picomolar concentration range
and that cytotoxicity is mediated by BiP cleavage. The changes in BiP
level in response to an EGF-SubA–induced insult progress through a
rapid and significant decline followed by up-regulation of BiP pro-
duction. In this respect, despite different routes of intracellular deliv-
ery, EGF-SubA is similar to the bacterial SubAB holotoxin [3,21].
The magnitude of the response to EGF-SubA varied across the group
of EGFR-positive cells evaluated in this study, and EGF-SubA–induced
toxicity did not directly correspond to the EGFR expression level. Most
likely, this reflects a more complex interplay between such cell-specific
processes as EGFR/ligand clathrin- and non–clathrin-mediated inter-
nalization and trafficking [22] and the magnitudes of ER stress and
UPR signaling in a particular cell line. The results obtained in tissue
culture translated well in animal tumor models. The ability of EGF
to compete with EGF-SubA for binding to EGFR in tissue culture
might indicate a possible limitation of EGF-SubA applicability in vivo.
However, the accumulated experience with EGF-toxin fusion pro-
teins [8,16], as well as multiple publications on targeted in vivo imag-
ing of tumor EGFR with EGF-based tracers [10, and supplementary
material herein; 23,24] suggests that EGF-SubA would successfully
compete with endogenous EGF for binding to and internalization into
EGFR-positive tumor cells in vivo.
The dependence on GRP78/BiP for cell survival is cell specific
[25,26]. Suzuki et al. [27] demonstrated that two of seven tested cell
lines, PC3 and HeLa, underwent apoptosis after transfection with
GRP78/BiP siRNA. However, for most cancer cell lines, down-
regulation of GRP78/BiP through antisense and RNA interference
approaches is not cytotoxic [5–7]. We reason that the rapid cleavage
of BiP, as opposed to slower down-regulation through antisense and
RNAi methods, is primarily responsible for the irreversible cytotoxic
effects of EGF-SubA. Mechanistically, it is possible that the rapid re-
lease of ER stress transducers activating transcription factor 6, inositol-
requiring enzyme 1, and PKR-like ER kinase, as reported recently for
the SubAB holotoxin [15], cannot be efficiently compensated by slower
up-regulation of GRP78/BiP expression or by other protective path-
ways. Alternatively, the cleavage of GRP78/BiP might result in the
opening of translocation pores in the ER, for example, at the luminal
end of the Sec61 translocon pore [28], which, in turn, activates addi-
tional mechanisms of cell destruction.
Our main finding is that treating cells undergoing ER stress with
EGF-SubA has a potent synergistic effect on cellular cytotoxicity. In
contrast, the combinations of EGF-SubA with drugs that do not in-
duce ER stress produce mostly additive effects. A logical explanation
for such selective synergism would be the ability of EGF-SubA to sab-
otage cell reliance on GRP78/BiP in developing a protective response to
ER stress [29]. This is the first example of mechanism-based synergism
in the action of immunotoxin and ER-targeting drugs, and it provides
a new paradigm for the rational design of combination regimens for
anticancer therapy. Importantly, such therapy would target not only
EGFR-positive cancer cells but also EGFR-expressing tumor endothe-
lial cells [30].
Is there translational significance in our findings? So far, attempts to
use targeted immunotoxins have distinctively mixed records [8,16].
Problems with systemic toxicity, aggravated by preexisting immunity,
prevented or terminated clinical development of several immunotoxins,
including EGF-DT [31–33]. The preexisting immunity to DTmoiety
originates from diphtheria-tetanus-pertussis vaccine that provides for a
high immunization level and a long-memory immune response. In-
deed, 25% of the breast cancer patients involved in EGF-DT phase
1/2 clinical trials had high pretreatment DT antibody titers, and all
patients had high DT-specific antibody titers 1 month after treatment
[34]. From this standpoint, EGF-SubA is a more suitable candidate for
clinical development.
Nevertheless, ER stress inducers, such as thapsigargin or tunica-
mycin, also display unacceptable systemic toxicity, and their formula-
tion might require reengineering either as targeted drugs or prodrugs
[17]. Our results suggest that EGF-SubA in combination with syner-
gistic ER stress–inducing drugs might be effective at significantly lower
doses than required for monotherapy. Furthermore, a nonlinear de-
crease in sensitivity to EGF-SubA cells observed for cells with low
physiological levels of EGFR expression may provide an additional
level of safety for normal tissue. Because EGFR overexpression is asso-
ciated with invasiveness and metastatic potential of tumor cells [35],
we suggest that EGF-SubA/drug combinations might be particularly
effective against metastatic tumors. Given the additional advantages
of cytotoxic activity against confluent cells and the absence of pre-
existing immunity to SubAB, targeting BiP with EGF-SubA or other
targeted SubA cytotoxins might provide unique translational opportuni-
ties for a rational mechanism-based design of combination treatments.
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Figure W1. Construction of chimeric toxins. All proteins con-
structed for this study contain an N-terminal 15–amino acid cysteine-
containing tag (Cys-tag) designed for site-specific conjugation of
recombinant proteins [9,10]. For this work, we used a Cys-tag in EGF-
SubA for site-specificmodificationwith amaleimide derivative of Alexa
Fluor 594. The resulting EGF-SubA* was used as a fluorescent tracer
for cell microscopy and immunohistochemical experiments. Three
control proteins were cloned in the same the pET/Hu-R4C(G4S)3
vector. SubA: To evaluate the toxicity of the nontargeted SubA pro-
tein, SubA was cloned in-framewith the Cys-tag as described in the
Materials and Methods section for EGF-SubA, except without the
EGFmoiety. EGF-ciSubA: To confirm a causative role for SubA enzy-
matic activity in the toxic effects of EGF-SubA, we constructed an
EGF-ciSubA protein containing catalytically inactive (ci) SubA. DNA
encoding a catalytically inactive mutant of SubA with the S272A
amino acid substitution was amplified by PCR from the pK184-
subAA272B plasmid described elsewhere [4]. EGF-StxA: To compare
the effects of EGF-SubA with an EGF-based fusion toxin acting
through different mechanism(s), we fused EGF to the full-length sub-
unit A of Shiga toxin (StxA). DNA encoding StxA was amplified by
PCR from the pJB144 plasmid (kindly provided by Dr. A. Soltyk,
Samuel Lunfield Research Institute, Toronto, Canada) and cloned
in-frame with EGF. Functional activity of EGF-StxA is shown in
Figure W6. All four recombinant chimeric toxins were expressed
in E. coli strain BL21(DE3), refolded from inclusion bodies and puri-
fied as described [9].
Figure W2. Expression, purification, and tissue culture testing of EGF-SubA. (A) SDS-PAGE analysis of bacterial expression and puri-
fication of EGF-SubA. Typical recovery and quality of purification by ion exchange chromatography (prepacked 1-ml Q-column; GE
Healthcare) is shown. Samples were separated on 15% reducing gels and stained by SafeBlue stain (BioRad, Hercules, CA). Lanes:
1, uninduced culture; 2, isopropyl β-D-1-thiogalactopyranoside–induced culture; 3, total bacterial homogenate; 4, soluble part of bacte-
rial homogenate; 5, insoluble part; 6, protein purified by ion exchange chromatography migrates as single prominent band with apparent
molecular mass of 45 kDa. M, prestained molecular weight markers (BioRad). (B) Functional activity of EGF-SubA and fluorescent con-
jugate EGF-SubA* was tested on EGFR-positive breast cancer cells MDA231luc. Cells were plated in 96-well plates at 2000 cells per well
20 hours before the experiment. EGF-SubA and EGF-SubA* were diluted in complete culture medium and added to cells in triplicate
wells. Cells were incubated under normal culture conditions for 72 hours and then viable cells were detected by CellTiter 96 AQueous
One Solution Cell Proliferation assay (Promega).
Figure W3. Expression of EGFR and BiP in cancer cells used in this study. (A) For estimation of EGFR expression, we used F98-EGFR
and F98-EGFR(F) cells with known EGFR per cell (Table 1). Each cell line was incubated with a PE-labeled rat anti–human EGFR–specific
antibody (AbCam), washed once with PBS buffer after a 30-minute incubation, and analyzed on a FACScan flow cytometer (Becton
Dickinson, San Diego, CA) equipped with CELLQuest software. An irrelevant PE-labeled rat anti–human IL-10 (PharMingen, San Diego,
CA) antibody was used as a negative control for the nonspecific binding of cells to PE-conjugated rat antibodies. (B) Cell lysates of
untreated human cancer cells MDA231luc, PC3, and MCF-7 were made as described in the legend to Figure 1. Equal numbers of cell
equivalents were analyzed side-by-side by Western blot analysis.
Figure W4. The pattern of EGF-SubA–induced BiP cleavage is cell-
specific and critically depends on both EGF and SubA moieties.
Cells were plated in six-well plates, 0.5 million/well and exposed to
EGF-SubA 20 hours later. (A) MDA231luc cells were exposed to
1 nM SubA for the indicated times, lysed, and analyzed by Western
blot analysis with BiP-specific antibody from Santa Cruz Biotech-
nology. (B) PC3 and MDA231luc cells were exposed to varying
EGF-SubA concentrations for 72 hours, then lysed and analyzed
by Western blot analysis with a BiP-specific antibody from R&D Sys-
tems. (C) EGF-ciSubA is not toxic for the most susceptible PC3 cells.
PC3 were plated in 96-well plates at 2000 cells per well 20 hours
before the experiment. EGF fusionproteins, EGF-SubAorEGF-ciSubA,
were diluted in complete culture medium and added to cells in trip-
licatewells. Viable cellsweredetermined96hours later by theCellTiter
assay (Promega).
Figure W5. Fractional addition is more cytotoxic at low doses of
EGF-SubA. MDA231luc cells were plated into 96-well plates at
2000 cells/50 μl per well. Twenty-four hours later, EGF-SubA was
serially diluted in complete culture medium and added to cells in
triplicate wells to a final volume of 0.1 ml/well. After a 24-hour in-
cubation under normal culture conditions, EGF-SubA was added
to cells scheduled to receive two doses of cytotoxin. EGF-SubA
was serially diluted in complete culture medium and added to
wells to double its concentration in each well and make a final vol-
ume of 0.15 ml/well. To maintain uniform volumes in all wells,
cells exposed to single dose of EGF-SubA were supplemented
with 50 μl per well of complete culture medium. After a total ex-
posure of 114 hours, the numbers of viable cells were determined
by the CellTiter assay (Promega).
Figure W7. Lack of synergism in combinations of EGF-SubA with drugs that induce low to no up-regulation of GRP78/BiP. (A) BiP
expression in MDA231luc cells after 24 hours of exposure to 2 μM bortezomib or 1 μM doxorubicin was analyzed as described in legend
to Figure 2. (B) MDA231luc cells were exposed to bortezomib, alone (Bort) or in combination with EGF-SubA at a molar ratio of 2000:1.
(C) MDA231luc cells were exposed to doxorubicin, alone (DOX) or in combination with EGF-SubA at a molar ratio of 1000:1. Cell viability
was determined after 72 hours.
Figure W6. Functional activity of EGF-StxA. (A) Activity of EGF moiety was tested by the ability of EGF-StxA fusion protein to induce
EGFR tyrosine autophosphorylation in F98-EGFR cells as described in legend to Figure 1A. (B) Because StxA inhibits protein synthesis by
targeting 28S ribosomal RNA, functional activity of the StxA domain in EGF-StxA was tested by its ability to terminate in vitro translation
of luciferase mRNA as described elsewhere [13]. The reaction was completely terminated in the presence of 1 nM EGF-StxA. The control
reaction was incubated with bacterially expressed Cys-tagged EGF [10, and supplementary material herein]. (C) The ability to inhibit
growth of MDA231luc cells was tested as described in the legend to Figure 2B. EGF-StxA inhibited MDA231luc cell growth with an
IC50 of 60 ± 10 pM. The fusion protein containing StxA and an unrelated growth factor, human VEGF, was described elsewhere [13]. We
used VEGF-StxA to compare EGFR-mediated and nonspecific StxA cytotoxicity for MDA231luc cells.
